Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R0TE
|
||||
| Former ID |
DNC005718
|
||||
| Drug Name |
3-(6-Ethoxy-naphthalen-2-yl)-pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527801] | ||
| Formula |
C17H15NO
|
||||
| Canonical SMILES |
CCOC1=CC2=C(C=C1)C=C(C=C2)C3=CN=CC=C3
|
||||
| InChI |
1S/C17H15NO/c1-2-19-17-8-7-13-10-14(5-6-15(13)11-17)16-4-3-9-18-12-16/h3-12H,2H2,1H3
|
||||
| InChIKey |
CQLHDOYGDGBDQA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [527801] | |
| Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [527801] | ||
| 17 alpha-hydroxylase-C17, 20-lyase | Target Info | Inhibitor | [527801] | ||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Ovarian Infertility Genes | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
| Corticotropin-releasing hormoneWP702:Metapathway biotransformation | |||||
| Steroid Biosynthesis | |||||
| Glucocorticoid & Mineralcorticoid Metabolism | |||||
| Prostate Cancer | |||||
| Phase 1 - Functionalization of compounds | |||||
| References | |||||